Shares of Acelyrin tumbled after the company said it would stop developing its eye-disease treatment following results from a recent study. The stock fell 16%, to $3.39, in after-hours trading Tuesday ...
but months later with no improvement an optometrist diagnosed her with dry eye disease. "They said because of my lifestyle, working from home where I'm constantly on the computer, it could stem ...